Reply

Ophthalmology. 2016 Feb;123(2):e13-e14. doi: 10.1016/j.ophtha.2015.08.032.

Authors

Annabelle A Okada¹, Akiko Yamamoto², Hideki Koizumi³, Mariko Kano⁴, Masaaki Saito⁴, Ichiro Maruko³, Tetsuju Sekiryu⁴, Tomohiro Iida³

Affiliations

¹ Kyorin University School of Medicine, Tokyo, Japan. Electronic address: aokada@eye-center.org.
² Kyorin University School of Medicine, Tokyo, Japan.
³ Tokyo Women's Medical University, Tokyo, Japan.
⁴ Fukushima Medical University, Fukushima, Japan.

PMID: 26802715
DOI: 10.1016/j.ophtha.2015.08.032

No abstract available

Publication types

Letter
Comment

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Choroidal Neovascularization / drug therapy*
Female
Humans
Male
Polyps / drug therapy*
Receptors, Vascular Endothelial Growth Factor / therapeutic use*
Recombinant Fusion Proteins / therapeutic use*

Substances

Angiogenesis Inhibitors
Recombinant Fusion Proteins
Receptors, Vascular Endothelial Growth Factor